Strategies to Improve the Safety of iPSC-Derived β Cells for β Cell Replacement in Diabetes

Abstract

Allogeneic islet transplantation allows for the re-establishment of glycemic control with the possibility of insulin independence, but is severely limited by the scarcity of organ donors. However, a new source of insulin-producing cells could enable the widespread use of cell therapy for diabetes treatment. Recent breakthroughs in stem cell biology, particularly pluripotent stem cell (PSC) techniques, have highlighted the therapeutic potential of stem cells in regenerative medicine. An understanding of the stages that regulate β cell development has led to the establishment of protocols for PSC differentiation into β cells, and PSC-derived β cells are appearing in the first pioneering clinical trials. However, the safety of the final product prior to implantation remains crucial. Although PSC differentiate into functional β cells in vitro, not all cells complete differentiation, and a fraction remain undifferentiated and at risk of teratoma formation upon transplantation. A single case of stem cell-derived tumors may set the field back years. Thus, this review discusses four approaches to increase the safety of PSC-derived β cells: reprogramming of somatic cells into induced PSC, selection of pure differentiated pancreatic cells, depletion of contaminant PSC in the final cell product, and control or destruction of tumorigenic cells with engineered suicide genes.

Keywords: beta cells; cell therapy; induced pluripotent stem cells; safety; type 1 diabetes mellitus.

FIGURE 1

Potential targets and strategies acting on different cell compartments for the induction of selective PSC death.

FIGURE 2

Schematic representation of gene editing strategies to increase the safety of iPSC-derived β cell transplantation. Gene-edited iPSC are differentiated into β cells and only insulin-positive cells are purified.